Biolevate's CEO, Joel Belafa, and COO, Nathan Chen, launched the prototype with the help of CTO Anas Laaroussi and CPO Antoine De Torcy. If the current strategy does not work, Belafa said the company would commercialize the platform for other industries, sell their individual models as an API, or offer a drug discovery professional service.
Key takeaways:
- Biolevate, a Paris-based company, has raised €6 million in a Seed funding round led by EQT Ventures. The company has developed a platform that uses NLP and visual document reading to assist medical writers, speeding up the labor-intensive process of documentation in drug development.
- The company was founded by Joel Belafa and Nathan Chen, who combined their expertise in AI and pharmaceutical processes to create their first prototype, Elise.
- The platform optimizes the creation and management of research and compliance documents, working as an AI assistant to medical writers. It guides a writer through the materials, reducing the time and effort needed to understand or correct the system.
- If the current strategy does not work, Biolevate plans to commercialize their platform as a service for other industries, sell their individual models as an API, or use it to offer a drug discovery professional service.